Lactobacillus paracasei BN07 for relieving allergic rhinitis and allergic dermatitis and application of lactobacillus paracasei BN07
Through C. paracetaccharin BN07 and its fermented substances, the drug resistance and toxic side effects caused by the long-term use of hormone drugs have been solved, and allergic rhinitis and dermatitis have been significantly alleviated, achieving safe and efficient long-term effects.
Patent Information
- Application Number
- CN202410833160.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-26
- Publication Date
- 2024-11-26
AI Technical Summary
In the prior art, hormone drugs are used to relieve allergic rhinitis and dermatitis, which have complications such as increased drug resistance after long-term use, liver and kidney damage and metabolic disorders, and have great toxic side effects on the body, making it difficult to effectively allergic. reaction.
The use of Lacticaeibacillus paracasei BN07 and its fermented substances significantly relieves allergic rhinitis and dermatitis symptoms by reducing the content of inflammatory factors and cytokines, and does not cause damage to the body due to its symbiotic nature.
C. paracetacci BN07 can significantly relieve allergic rhinitis and dermatitis, have safe effects, have no toxic side effects in long-term use, continue to exert probiotic effects, reduce the levels of inflammatory factors and cytokines, and improve the persistence and safety of treatment.
Smart Images

Figure BDA0004912382430000071 
Figure BDA0004912382430000072 
Figure BDA0004912382430000073
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of probiotics, and in particular to Lactobacillus paracasei BN07 for relieving allergic rhinitis and allergic dermatitis and application thereof. Background Art
[0002] Allergic rhinitis is an inflammatory disease of the nasal mucosa. It can be induced by eating or inhaling allergens, congenital heredity, air pollution and external infection. When it occurs, the human body will experience uncomfortable symptoms such as frequent sneezing, runny nose, itching and congestion. In severe cases, it will also cause a series of complications, such as sinusitis and bronchial asthma, which are harmful to human health. Allergic dermatitis is an inflammatory disease of the skin. It can be induced by contact with allergens (such as: animal allergens such as various animal furs and toxins; plant allergens such as leaves, stems, flowers and fruits of plants; chemical substances such as drugs, detergents, cosmetics, chemical raw materials, dyes, etc.), changes in air humidity / temperature, etc. When it occurs, the human body will experience uncomfortable symptoms such as skin erythema, rash, itching, etc. In severe cases, it will also cause skin edema and ulceration, which are harmful to human health.
[0003] Most of the drugs on the market for allergic symptoms are hormones. Although they can provide temporary improvement, long-term use will lead to tissue rigidity at the site of administration, tissue cell mutation and drug resistance, aggravation of allergic symptoms, and increased difficulty in treatment. In addition, with the superposition and cumulative use of multiple hormone drugs, it will also lead to complications such as liver and kidney damage, metabolic disorders, and endocrine disorders, which are harmful to human health.
[0004] The intestinal flora is large and complex, with a total number of about 1014 microorganisms, which is 10 times the number of human cells. They are always involved in the physiological activities of the human body and are closely related to human health. Relieving allergic reactions through microorganisms is not only sustainable, that is, the live bacteria colonize and proliferate in the intestines, and their own metabolites can continue to increase, thereby exerting a probiotic effect, but also because the number of beneficial bacteria microorganisms is large, the proliferation rate is fast, and they survive in the human intestine and coexist with the human body, so they will not cause damage to the body or any toxic side effects. They can gently and efficiently relieve allergic reactions from the inside out, and the effect is better if consumed for a long time. Summary of the invention
[0005] In order to overcome the deficiencies of the prior art, one of the objectives of the present invention is to provide a Lacticaseibacillus paracasei BN07 for alleviating allergic inflammation.
[0006] A second object of the present invention is to provide a fermented product for allergic inflammation relief.
[0007] The third object of the present invention is to provide an application of Lactobacillus paracasei BN07 in the preparation of a product for treating allergic inflammation.
[0008] One of the purposes of the present invention is achieved by the following technical solution:
[0009] A strain of Lactobacillus paracasei for relieving allergic inflammation, wherein the Lactobacillus paracasei is Lactobacillus paracasei BN07, and the Lacticaseibacillus paracasei BN07 was deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration on November 22, 2023, with a deposit number of CGMCC No.29104; the allergic inflammation is allergic rhinitis and / or allergic dermatitis.
[0010] As a preferred embodiment of the present invention, the Lactobacillus paracasei BN07 exerts the effect of relieving allergic rhinitis through one or more of the following items (I) to (IV):
[0011] (Ⅰ) Reduce nose scratching;
[0012] (II) Reduce sneezing;
[0013] (III) Reduce runny nose;
[0014] (IV) Reduce the levels of inflammatory factors IL-12, TNF-α, and IL-6.
[0015] As a preferred embodiment of the present invention, the Lactobacillus paracasei BN07 exerts the effect of relieving allergic dermatitis through one or more of the following items (I) to (II):
[0016] (Ⅰ) Reduce skin itching;
[0017] (Ⅱ) Reduce the levels of cytokines IL-4, IL-5, and IL-13.
[0018] The second object of the present invention is achieved by adopting the following technical solution:
[0019] A Lactobacillus paracasei fermented product for relieving allergic inflammation, wherein the fermented product is fermented by Lacticaseibacillus paracasei BN07, and the Lacticaseibacillus paracasei BN07 was deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration on November 22, 2023, with a deposit number of CGMCC No.29104; the allergic inflammation is allergic rhinitis and / or allergic dermatitis.
[0020] As a preferred embodiment of the present invention, the fermented product is a fermented bacterial suspension of Lactobacillus paracasei BN07.
[0021] As a preferred embodiment of the present invention, the fermented product is a composite bacterial suspension, which includes a bacterial suspension of Lactobacillus paracasei BN07 and one or more of the following bacterial suspensions: a suspension of Lactobacillus rhamnosus BN06, a suspension of Lactobacillus plantarum BN03, a suspension of Lactobacillus fermentum BN11, and a suspension of Bifidobacterium animalis subspecies lactis BN12.
[0022] As a preferred embodiment of the present invention, the composite bacterial suspension is formed by mixing a bacterial suspension of Lacticaseibacillus paracasei BN07, a bacterial suspension of Lactobacillus rhamnosus BN06, a bacterial suspension of Lactobacillus plantarum BN03 and a bacterial suspension of Bifidobacterium animalis subsp. lactis BN12.
[0023] As a preferred embodiment of the present invention, the volume ratio of the Lacticaseibacillus paracasei BN07 bacterial suspension, the Lactobacillus rhamnosus BN06 bacterial suspension, the Lactobacillus plantarum BN03 bacterial suspension and the Bifidobacterium animalis subsp. lactis BN12 bacterial suspension is (1-3):1:(1-2):1.
[0024] As a preferred embodiment of the present invention, the volume ratio of the Lacticaseibacillus paracasei BN07 bacterial suspension, the Lactobacillus rhamnosus BN06 bacterial suspension, the Lactobacillus plantarum BN03 bacterial suspension and the Bifidobacterium animalis subsp. lactis BN12 bacterial suspension is 3:1:2:1.
[0025] The third object of the present invention is achieved by adopting the following technical solution:
[0026] The present invention also provides the use of Lacticaseibacillus paracasei BN07 in preparing a product for treating allergic inflammation, wherein the allergic inflammation is allergic rhinitis and / or allergic dermatitis.
[0027] Compared with the prior art, the present invention has the following beneficial effects:
[0028] (1) The Lactobacillus paracasei for relieving allergic inflammation provided by the present invention is Lactobacillus paracasei BN07, which can relieve both allergic rhinitis and allergic dermatitis, has significant effects, and is healthy and safe.
[0029] Biological material preservation information: Lactobacillus paracasei BN07, the preservation number is CGMCC No.29104, the classification name is: Lacticaseibacillus paracasei, it was deposited on November 22, 2023 in the General Microbiology Center of China Culture Collection Administration (Address: No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, Postal Code: 100101), and the abbreviation of the depository unit is CGMCC.
[0030] Lactobacillus rhamnosus BN06, with the deposit number CGMCC No.29103 and the classification name: Lacticaseibacillus rhamnosus, was deposited on November 22, 2023 at the General Microbiology Center of China Culture Collection Administration (address: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, Postal Code: 100101), and the abbreviation of the depository unit is CGMCC.
[0031] Lactobacillus plantarum BN03, with the deposit number CGMCC No.29101, is classified and named: Lactobacillus plantarum. It was deposited on November 22, 2023 at the General Microbiology Center of China Culture Collection Administration (address: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, Postal Code: 100101). The abbreviation of the depository unit is CGMCC.
[0032] Bifidobacterium animalis subsp. lactis BN12, with the deposit number CGMCC No.29109, is classified and named as: Bifidobacterium animalis subsp. lactis. It was deposited on November 22, 2023 at the General Microbiology Center of China Culture Collection Administration (address: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, Postal Code: 100101). The abbreviation of the depository unit is CGMCC. DETAILED DESCRIPTION
[0033] The present invention is further described below in conjunction with specific embodiments. It should be noted that, under the premise of no conflict, the embodiments or technical features described below can be arbitrarily combined to form new embodiments. The raw materials, equipment, etc. used in the following embodiments can be purchased through commercial channels unless otherwise specified.
[0034] The embodiment of the present invention provides a strain of Lactobacillus paracasei for relieving allergic inflammation, which is Lactobacillus paracasei (Lacticaseibacillus paracasei) BN07, which was deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration on November 22, 2023, with a deposit number of CGMCC No.29104; the allergic inflammation is allergic rhinitis and / or allergic dermatitis.
[0035] The present invention also provides a Lactobacillus paracasei fermented product for relieving allergic inflammation, wherein the fermented product is fermented by Lacticaseibacillus paracasei BN07. The fermented product includes a fermented bacterial suspension of Lacticaseibacillus paracasei BN07.
[0036] System 1: Screening of strains that can relieve allergic rhinitis
[0037] 1. Experimental strains: Lactobacillus paracasei KL1 (preservation number: CGMCC No.11533), Lactobacillus paracasei BN07, Lactobacillus paracasei SR10-1 (preservation number: CCTCC No.M2016527).
[0038] 2. Experimental animals: SPF BALB / c male mice, 5 weeks old, weighing 16±1 g / mouse, were fed adaptively for 3 days before the experiment.
[0039] 3. Sample preparation:
[0040] (1) Physiological saline: Weigh 9 g of NaCl and dissolve it in 1000 mL of distilled water, stir to dissolve, and sterilize at 121°C for 20 min;
[0041] (2) Preparation of culture medium: 4 g / L yeast powder, 8 g / L beef extract, 20 g / L glucose, 5 g / L sodium acetate, 1 mL / L Tween-80, 2 g / L potassium dihydrogen phosphate, 10 g / L peptone, 2 g / L triammonium citrate, 0.2 g / L magnesium sulfate, and 0.05 g / L manganese sulfate. Dissolve and make up to volume with distilled water, adjust pH to 6.5, and sterilize at 121°C for 20 min.
[0042] (3) Preparation of bacterial suspension:
[0043] 1) Activation of bacterial strains: Take the strain frozen in glycerol, thaw it at 4°C, place it in a clean bench after ultraviolet disinfection for 30 minutes, take 40 μL of the thawed bacterial solution and place it in 4 mL of culture medium, culture it at 37°C, 180 r / min for 24 hours to obtain the first-level activation solution, then take 1 mL of the first-level activation solution and place it in 100 mL of culture medium, culture it at 37°C, 180 r / min for 24 hours, centrifuge it at 4°C, 8000 r / min for 10 minutes, and take the precipitate, which is the bacterial sludge.
[0044] 2) Fermentation: Add the bacterial sludge into the culture medium at a rate of 5%, culture at 37°C and 180 r / min for 24 h, and dilute with the culture medium to adjust the number of viable bacteria to 1×109 CFU / mL to obtain a bacterial suspension.
[0045] 4. Experimental methods:
[0046] (1) The mice were randomly divided into five groups: group A, group B, group C, group D, and group E, with 12 mice in each group.
[0047] (2) Modeling: Mice in group A were intraperitoneally injected with an equal dose of normal saline, and mice in the other groups were intraperitoneally injected with 2.5 mg / kg OVA and 50 mg / kg aluminum hydroxide (dissolved in PBS buffer) on days 1, 5, 10, and 15. Five days after the last injection of OVA sensitization, all groups except group A were challenged intranasally with OVA (0.5 mg / nostril) once a day for 7 consecutive days, and group A was not treated.
[0048] (3) After modeling, the mice were treated by gavage at 10 a.m. every day, once a day, for 10 consecutive days. The drug types and doses are shown in Table 1. The treatment was terminated 24 hours after the last gavage. Allergic rhinitis symptoms were scored for each group of mice before and after treatment according to the scoring criteria in Table 2. The symptom score was the sum of the scores of each observation condition. The average score of each group was calculated. The results are shown in Table 3.
[0049] Table 1 Intragastric administration of mice in each group
[0050]
[0051]
[0052] Table 2 Scoring criteria for allergic rhinitis during the observation period
[0053]
[0054] (4) Detection of inflammation-related factors: After the scoring, a catheter was inserted from the mouse's trachea to the nasopharynx, and the nasal cavity was cleaned with 1 mL of normal saline to collect the fluid. The nasal lavage fluid was collected after repeated operation and centrifuged at 4°C and 6000 r / min for 5 min. The supernatant was collected for detection of inflammation-related factor levels. The levels of IL-12, TNF-α, and IL-6 in the nasal lavage fluid of each group were detected according to the instructions of the ELISA kit. The results are shown in Table 4.
[0055] 5. Results and analysis:
[0056] Table 3 Allergic rhinitis symptom scores of mice in each group
[0057]
[0058] As shown in Table 3, compared with group A, the allergic rhinitis symptom scores of mice in groups B to E before treatment were all ≥5 points, indicating that the mice had obvious allergic rhinitis symptoms, indicating that the model was successfully established. Compared with before treatment, the allergic rhinitis symptom scores of mice in groups C to E after treatment were all reduced, indicating that after probiotic intervention, the allergic rhinitis symptoms of mice were improved, but the difference in the probiotics administered to mice in different groups resulted in different degrees of improvement. Among them, the allergic rhinitis symptom score of mice in group D after treatment was the lowest, indicating that the probiotics in group D had the best effect on improving allergic rhinitis, that is, Lactobacillus paracasei had the best effect on improving allergic rhinitis.
[0059] Table 4 Comparison of IL-12, TNF-α, and IL-6 levels in nasal lavage fluid of each group
[0060] Group IL-12 / (ng / mL) TNF-α / (pg / mL) IL-6 / (ng / mL) Group A 0.28±0.04 26.76±4.19 0.53±0.07 Group B 4.91±0.36 93.45±3.18 5.14±0.48 Group C 2.72±0.42 70.18±3.51 2.91±0.29 Group D 0.93±0.31 39.57±4.60 1.15±0.33 Group E 2.50±0.47 64.63±3.46 2.82±0.15
[0061] When an organism develops an allergic disease, the content of inflammatory factors in the body surges, and cytokines flood near the nasal mucosa, enhancing the inflammatory response and increasing the symptoms of allergic rhinitis. As shown in Table 4, compared with group A, the content of IL-12, TNF-α, and IL-6 in the nasal lavage fluid of group B increased significantly, indicating that the inflammatory response of allergic rhinitis in mice in group B was more severe. Compared with group B, the content of IL-12, TNF-α, and IL-6 in the nasal lavage fluid of groups C to E decreased, indicating that after probiotic intervention, the inflammatory response of allergic rhinitis in mice was improved, but the difference in the probiotics administered to mice in different groups resulted in different degrees of improvement. Among them, the content of IL-12, TNF-α, and IL-6 in the nasal lavage fluid of mice in group D was the lowest, indicating that the probiotics in group D had the best effect on improving the inflammatory response of allergic rhinitis, that is, Lactobacillus paracasei BN07 had the best effect on improving the inflammatory response of allergic rhinitis.
[0062] Therefore, combined with the experimental conclusions of Tables 3 and 4, Lactobacillus paracasei BN07 was selected as the best strain for relieving allergic rhinitis.
[0063] System 2: Screening of strains that can relieve allergic dermatitis
[0064] 1. Experimental strains: Lactobacillus paracasei KL1 (preservation number: CGMCC No.11533), Lactobacillus paracasei SR10-1 (preservation number: CCTCC No.M2016527), and Lactobacillus paracasei BN07.
[0065] 2. Experimental animals: SPF BALB / c male mice, 8 weeks old, weighing 22±1 g / mouse, were fed adaptively for 3 days before the experiment.
[0066] 3. Sample preparation:
[0067] (1) Physiological saline: Weigh 9 g of NaCl and dissolve it in 1000 mL of distilled water, stir to dissolve, and sterilize at 121°C for 20 min;
[0068] (2) Preparation of culture medium: 4 g / L yeast powder, 8 g / L beef extract, 20 g / L glucose, 5 g / L sodium acetate, 1 mL / L Tween-80, 2 g / L potassium dihydrogen phosphate, 10 g / L peptone, 2 g / L triammonium citrate, 0.2 g / L magnesium sulfate, and 0.05 g / L manganese sulfate. Dissolve and make up to volume with distilled water, adjust pH to 6.5, and sterilize at 121°C for 20 min.
[0069] (3) Preparation of bacterial suspension:
[0070] 1) Activation of bacterial strains: Take the strain frozen in glycerol, thaw it at 4°C, place it in a clean bench after ultraviolet disinfection for 30 minutes, take 40 μL of the thawed bacterial solution and place it in 4 mL of culture medium, culture it at 37°C, 180 r / min for 24 hours to obtain the first-level activation solution, then take 1 mL of the first-level activation solution and place it in 100 mL of culture medium, culture it at 37°C, 180 r / min for 24 hours, centrifuge it at 4°C, 8000 r / min for 10 minutes, and take the precipitate, which is the bacterial sludge.
[0071] 2) Fermentation: Add the bacterial sludge into the culture medium at a rate of 5%, culture at 37°C and 180 r / min for 24 h, and dilute with the culture medium to adjust the number of viable bacteria to 1×109 CFU / mL to obtain a bacterial suspension.
[0072] 4. Experimental methods:
[0073] (1) The mice were randomly divided into 5 groups, namely group A, group B, group C, group D, and group E, with 12 mice in each group;
[0074] (2) Modeling: All groups of mice were anesthetized by inhalation of isoflurane, and the abdomen was shaved (to avoid skin damage). Mice in groups B, C, D, and E were sensitized for 3 consecutive days using squaric acid dibutyl ester (SADBE), i.e., 1% SADBE (25 μL) dissolved in acetone was applied to the abdomen of the mice. After the 4th day of sensitization, all groups of mice were anesthetized by inhalation of isoflurane in a sedated state, and the right cheek was shaved (to avoid skin damage). After the cheek was shaved, mice in groups B, C, D, and E were continuously smeared with 1% SADBE (25 μL) on the shaved area of the right cheek twice, once a day.
[0075] (3) After modeling, the mice were treated by gavage at 10 a.m. every day, once a day, for 7 consecutive days. The drug types and doses are shown in Table 5. The treatment was terminated 24 hours after the last gavage. The number of pain and itching times of each group of mice before and after treatment was recorded according to the "pain and itch-like behavior assessment method". The results are shown in Table 6.
[0076] Table 5 Intragastric administration of mice in each group
[0077] Group Processing Group A 1.7 mL normal saline Group B 1.7 mL normal saline Group C 1.7mL Lactobacillus paracasei KL1 bacterial suspension Group D 1.7mL of Lactobacillus paracasei SR10-1 bacterial suspension Group E 1.7mL Lactobacillus paracasei BN07 bacterial suspension
[0078] (4) Assessment methods for pain and pruritus-like behaviors:
[0079] 1) Measurement of pain-like behavior
[0080] Before the pain-like behavior assessment, all mice need to adapt to the behavioral monitoring environment in advance. In this experiment, the behavioral monitoring environment is a 8×8×13cm transparent PVC observation box with breathing holes in a quiet environment, with horizontal mirrors at an angle of 45° placed around it. After the abdominal hair is shaved, all mice are placed in the behavioral monitoring environment and adapted to the environment 3 times, once a day, each time for 1 hour. 24 hours after the modeling of mice in groups B, C, D, and E, the mice were placed in the behavioral monitoring environment for monitoring for 30 minutes. All the movement behaviors of the mice were recorded by the camera on the top of the observation box and played back in a slow-motion player later. The quantification of pain-like behavior is defined as the number of times the right front paw of the mouse brushes the right cheek.
[0081] 2) Determination of itch-like behavior
[0082] Before the itch behavior assessment, all mice were required to adapt to the behavioral testing environment in advance. The itch-like behavior monitoring environment was the same as before, and the monitoring method was the same as the itch-like behavior. After the camera filmed and recorded the mouse behavior, a slow-motion player was used to replay the mouse's 30-min behavioral response. The itch-like behavior was quantified as the number of times the mouse's right hind paw scratched the right cheek.
[0083] (5) After the evaluation of the pain and itch-like behaviors of mice, all mice were treated with the cervical vertebrae sudden death method. 0.5 g of skin tissue after depilation of the abdomen and 0.1 g of skin tissue after depilation of the cheek of each mouse were taken and combined. A 3% skin tissue homogenate was made using an endo-type tissue homogenizer. The mixture was centrifuged at 4°C and 12,000 r / min for 10 min. The supernatant was taken and stored at -20°C. The contents of cytokines IL-4, IL-5, and IL-13 in the supernatant were detected using the cytokine ELISA kits. The results are shown in Table 7.
[0084] 5. Results and analysis:
[0085] Table 6 Symptoms of allergic dermatitis in mice in each group
[0086]
[0087] As shown in Table 6, compared with group A, the number of pain-like and itch-like behaviors of mice in groups B to E before treatment increased significantly, indicating that the model of allergic dermatitis mice was successfully established and the allergic dermatitis symptoms of mice were obvious. Compared with group B, the number of pain-like and itch-like behaviors of mice in groups C to E after treatment decreased significantly, and the allergic dermatitis symptoms of mice were improved, indicating that the drug-administered preparations of groups C to E, i.e., bacterial suspensions, have a relieving effect on allergic dermatitis. However, due to the differences between different strains, even the same strains have different degrees of relief. Among them, the number of pain-like and itch-like behaviors of mice in group E after treatment was the lowest, indicating that its drug-administered preparation, i.e., the suspension of Lactobacillus paracasei BN07, has the best relieving effect on allergic dermatitis.
[0088] Table 7 Comparison of the contents of cytokines IL-4, IL-5, and IL-13 in the supernatant
[0089] Group IL-4 / (pg / mL) IL-5 / (pg / mL) IL-13 / (pg / mL) Group A 4.35±0.03 1.87±0.05 2.06±0.10 Group B 9.61±0.85 4.10±0.79 3.41±0.47 Group C 6.03±0.14 2.99±0.07 2.73±0.01 Group D 8.17±0.06 3.46±0.16 3.08±0.11 Group E 4.48±0.17 1.93±0.08 2.17±0.04
[0090] As shown in Table 7, compared with Group A, the contents of cytokines IL-4, IL-5, and IL-13 in the supernatant of skin tissue homogenate of Group B increased significantly, indicating that the inflammation level of allergic dermatitis in mice in Group B was high and the symptoms were severe. Compared with Group B, the contents of cytokines IL-4, IL-5, and IL-13 in the supernatant of skin tissue homogenate of Groups C to E decreased significantly, and the inflammation level of allergic dermatitis in mice was alleviated. However, due to the differences between different strains, even the same strains had different degrees of relief. Among them, the contents of cytokines IL-4, IL-5, and IL-13 in the supernatant of skin tissue homogenate of Group E were the lowest, indicating that the inflammation level of allergic dermatitis in mice in Group E was the best, that is, its administration preparation - Lactobacillus paracasei BN07 bacterial suspension had the best effect on allergic dermatitis.
[0091] Therefore, in combination with the experimental conclusions of Table 6 and Table 7, select Lactobacillus paracasei BN07 as the best strain for allergic dermatitis relief.
[0092] System 3: Screening of bacterial strains for allergic rhinitis and allergic dermatitis
[0093] 1. Experimental strains: Lactobacillus rhamnosus BN06, Lactobacillus plantarum BN03, Lactobacillus fermentum BN11, Lactobacillus paracasei BN07, Bifidobacterium animalis subsp. lactis BN12.
[0094] 2. Sample preparation:
[0095] (1) Preparation of physiological saline: Weigh 9 g of NaCl and dissolve it in 1000 mL of distilled water, stir to dissolve, and sterilize at 121°C for 20 min;
[0096] (2) Preparation of culture medium: 4 g / L yeast powder, 8 g / L beef extract, 20 g / L glucose, 5 g / L sodium acetate, 1 mL / L Tween-80, 2 g / L potassium dihydrogen phosphate, 10 g / L peptone, 2 g / L triammonium citrate, 0.2 g / L magnesium sulfate, and 0.05 g / L manganese sulfate. Dissolve and make up to volume with distilled water, adjust pH to 6.5, and sterilize at 121°C for 20 min.
[0097] (3) Preparation of composite bacterial suspension:
[0098] 1) Activation of bacterial strains: Take the strain frozen in glycerol, thaw at 4°C, place it in a clean bench after UV disinfection for 30 minutes, take 40 μL of the thawed bacterial solution and place it in 4 mL of culture medium, culture it at 37°C, 180 r / min for 24 hours to obtain the first-level activation solution, then take 1 mL of the first-level activation solution and place it in 100 mL of culture medium, culture it at 37°C, 180 r / min for 24 hours, centrifuge it at 4°C, 8000 r / min for 10 minutes, and take the precipitate, which is the bacterial sludge;
[0099] 2) Fermentation: Add 5% of the bacterial sludge to the culture medium, culture at 37°C and 180 r / min for 24 h, and dilute with the culture medium to adjust the viable bacterial count to 1×109 CFU / mL to obtain a single bacterial suspension;
[0100] 3) Compounding: Take the single bacterial suspension according to the proportions in Table 8 and mix well with a vortex mixer to obtain a composite bacterial suspension.
[0101] Table 8 Compound bacterial suspension formula
[0102] Example BN06 BN03 BN07 BN12 1 1 1 1 1 2 0 2 3 1 3 3 0 2 3 4 2 3 0 2 5 1 2 3 0 6 1 2 3 1
[0103] 3. The composite bacterial suspension of each embodiment was tested according to the method of system 1 and system 2. The results are shown in Table 9, Table 10, Table 11 and Table 12.
[0104] 4. Results and analysis:
[0105] Table 9 Allergic rhinitis symptom scores of mice administered with different examples
[0106]
[0107] As can be seen from Table 9, compared with before treatment, the scores of allergic rhinitis in mice after treatment were all reduced, indicating that the composite bacterial suspensions of Examples 1 to 6 have an improving effect on allergic rhinitis in mice, but different examples have different effects. The score of mice in Example 6 after treatment is the lowest, indicating that Example 6 has the best effect on allergic rhinitis relief in mice.
[0108] Table 10 Comparison of IL-12, TNF-α, and IL-6 contents in mouse nasal lavage fluid
[0109]
[0110]
[0111] It can be seen from Table 10 and Table 4 that, compared with Group B of System 1, after the mice were treated with the composite bacterial suspensions of different embodiments, the contents of IL-12, TNF-α, and IL-6 in the nasal lavage fluid of the mice were reduced, indicating that the level of nasal inflammation was reduced, but different embodiments had different effects. The contents of IL-12, TNF-α, and IL-6 in the nasal lavage fluid of the mice treated with Example 6 were the lowest, indicating that the level of nasal inflammation in the mice was the lowest, that is, Example 6 had the best effect on allergic rhinitis relief in mice.
[0112] Table 11 Symptoms of allergic dermatitis in mice given different examples
[0113]
[0114] It can be seen from Table 11 that compared with before treatment, after the mice were treated with the composite bacterial suspensions of different embodiments, the number of pain-like behaviors and itching-like behaviors of the mice decreased, indicating that the allergic dermatitis of the mice was improved. However, due to the differences in the formulations of different composite bacterial suspensions, the degree of improvement of the allergic dermatitis of the mice was different. The composite bacterial suspension of Example 6 had the greatest degree of reduction in the number of pain-like behaviors and itching-like behaviors of the mice, indicating that it had the best effect on improving the allergic dermatitis of the mice.
[0115] Table 12 Comparison of the contents of cytokines IL-4, IL-5, and IL-13 in the supernatant
[0116] Example IL-4 / (pg / mL) IL-5 / (pg / mL) IL-13 / (pg / mL) 1 4.53±0.13 2.17±0.05 2.25±0.15 2 6.01±0.33 2.70±0.38 2.93±0.07 3 5.91±0.30 2.58±0.27 2.74±0.24 4 6.94±0.37 3.16±0.14 2.98±0.16 5 5.76±0.18 2.35±0.10 2.56±0.19 6 4.30±0.01 1.83±0.03 2.00±0.08
[0117] It can be seen from Table 12 and Table 7 that, compared with Group B of System 2, after the mice were treated with the composite bacterial suspensions of different embodiments, the contents of cytokines IL-4, IL-5, and IL-13 in the supernatant of the skin tissue homogenate of the mice were reduced, indicating that the inflammation level of the allergic dermatitis in the mice was decreased and the allergic dermatitis in the mice was improved, but different embodiments had different effects. The contents of cytokines IL-4, IL-5, and IL-13 in the supernatant of the skin tissue homogenate of the mice treated with Example 6 were the lowest, indicating that the improvement effect of the allergic dermatitis in the mice was the best.
[0118] In summary, after the composite bacterial suspension of Example 6 was administered to mice, the allergic rhinitis and allergic dermatitis of the mice were significantly improved. Therefore, the composite bacterial formulation of Example 6 was selected as the best bacterial strain formulation for relieving allergic rhinitis and allergic dermatitis.
[0119] The above-mentioned embodiments are only preferred embodiments of the present invention and cannot be used to limit the scope of protection of the present invention. Any non-substantial changes and substitutions made by technicians in this field on the basis of the present invention shall fall within the scope of protection required by the present invention.
Claims
1. A strain of Lactobacillus paracasei for allergic inflammation relief, characterized in that: The Lactobacillus paracasei is Lactobacillus paracasei BN07, which was deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration on November 22, 2023, with a deposit number of CGMCC No.29104; the allergic inflammation is allergic rhinitis and / or allergic dermatitis.
2. The Lactobacillus paracasei for allergic inflammation relief as claimed in claim 1, characterized in that The Lactobacillus paracasei BN07 can relieve allergic rhinitis through one or more of the following items (I) to (IV): (Ⅰ) Reduce nose scratching; (II) Reduce sneezing; (III) Reduce runny nose; (IV) Reduce the levels of inflammatory factors IL-12, TNF-α, and IL-6.
3. The Lactobacillus paracasei for alleviating allergic inflammation as claimed in claim 1, characterized in that The Lactobacillus paracasei BN07 exerts the effect of relieving allergic dermatitis through one or more of the following items (I) to (II): (Ⅰ) Reduce skin itching; (Ⅱ) Reduce the levels of cytokines IL-4, IL-5, and IL-13.
4. A Lactobacillus paracasei fermented product for alleviating allergic inflammation, characterized in that: The fermented product is fermented by Lacticaseibacillus paracasei BN07, and the Lacticaseibacillus paracasei BN07 was deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration on November 22, 2023, with a deposit number of CGMCC No.29104; the allergic inflammation is allergic rhinitis and / or allergic dermatitis.
5. The Lactobacillus paracasei fermented product for alleviating allergic inflammation as claimed in claim 4, characterized in that The fermented product is a fermented bacterial suspension of Lactobacillus paracasei BN07.
6. The Lactobacillus paracasei fermented product for allergic inflammation relief as claimed in claim 4, characterized in that The fermented product is a composite bacterial suspension, which includes a bacterial suspension of Lactobacillus paracasei BN07 and one or more of the following bacterial suspensions: a bacterial suspension of Lactobacillus rhamnosus BN06, a bacterial suspension of Lactobacillus plantarum BN03, a bacterial suspension of Lactobacillus fermentum BN11, and a bacterial suspension of Bifidobacterium animalis subspecies lactis BN12.
7. The Lactobacillus paracasei fermented product for alleviating allergic inflammation according to claim 6, characterized in that: The composite bacterial suspension is prepared by mixing a bacterial suspension of Lacticaseibacillus paracasei BN07, a bacterial suspension of Lactobacillus rhamnosus BN06, a bacterial suspension of Lactobacillus plantarum BN03 and a bacterial suspension of Bifidobacterium animalis subspecies lactis BN12.
8. The Lactobacillus paracasei fermented product for alleviating allergic inflammation according to claim 7, characterized in that: The volume ratio of the Lacticaseibacillus paracasei BN07 bacterial suspension, the Lactobacillus rhamnosus BN06 bacterial suspension, the Lactobacillus plantarum BN03 bacterial suspension and the Bifidobacterium animalis subspecies lactis BN12 bacterial suspension is (1-3):1:(1-2):
1.
9. The Lactobacillus paracasei fermented product for alleviating allergic inflammation according to claim 7, characterized in that: The volume ratio of the Lacticaseibacillus paracasei BN07 bacterial suspension, the Lactobacillus rhamnosus BN06 bacterial suspension, the Lactobacillus plantarum BN03 bacterial suspension and the Bifidobacterium animalis subspecies lactis BN12 bacterial suspension is 3:1:2:
1.
10. Use of Lacticaseibacillus paracasei BN07 in the preparation of a product for treating allergic inflammation, wherein the allergic inflammation is allergic rhinitis and / or allergic dermatitis.
Citation Information
Cited By
Bifidobacterium animalis subsp. Lactis BN12 for protecting intestinal health and fermented product
CN118207124A
Lactobacillus mucilaginosus BN11 for improving oral health and application of lactobacillus mucilaginosus BN11
CN118480471A
Fermented mucus lactobacillus BN11 for improving oral health and application thereof
CN118480471B
Lactobacillus paracasei LC97 for relieving allergy and application, product and method thereof
CN119331791A
Application of lactobacillus rhamnosus in preparation of preparation for relieving allergic rhinitis
CN120022297A
